Department of Urology, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin 53705-2281, USA.
J Urol. 2013 Aug;190(2):452-7. doi: 10.1016/j.juro.2013.02.033. Epub 2013 Feb 19.
Patients with renal cell carcinoma who present with pulmonary embolism and venous thrombus may not be offered surgery because of presumed poor postoperative outcomes. In this multicenter study we evaluated perioperative mortality, recurrence and cancer specific survival in patients with renal cell carcinoma and venous thrombus diagnosed with preoperative pulmonary embolism.
We reviewed consecutive patient records from our 3 tertiary hospitals to identify patients with renal cell carcinoma and venous thrombus treated with surgery from 2000 to 2011. Univariate and multivariate Cox proportional hazards analysis was used to evaluate whether preoperative pulmonary embolism or other clinical variables were associated with postoperative disease recurrence or cancer specific survival.
Pulmonary embolism was identified preoperatively in 35 of 782 patients (4.4%) with renal cell carcinoma. Those with pulmonary embolism preoperatively were more likely to have higher level thrombus and higher T stage (p <0.01). No differences were found in other clinical or pathological features between the groups. There was no difference in 90-day mortality in patients diagnosed with pulmonary embolism preoperatively. Of 395 patients without metastasis preoperatively 147 (37.2%) showed metastatic renal cell carcinoma at a median followup of 22 months. There was no difference in the recurrence rate of renal cell carcinoma in patients with pulmonary embolism (p = 0.36). Recurrence in the lung was not more common in patients with vs without pulmonary embolism preoperatively (p = 0.71). Also, preoperative pulmonary embolism was not predictive of worse cancer specific survival (p = 0.58).
Preoperative pulmonary embolism is not associated with worse early mortality, recurrence or cancer specific survival in patients with renal cell carcinoma and tumor thrombus.
患有肺栓塞和静脉血栓的肾细胞癌患者可能因术后预后不佳而不接受手术。在这项多中心研究中,我们评估了术前诊断为肺栓塞的肾细胞癌伴静脉血栓患者的围手术期死亡率、复发率和癌症特异性生存率。
我们回顾了我们 3 家三级医院的连续患者记录,以确定 2000 年至 2011 年接受手术治疗的肾细胞癌和静脉血栓患者。使用单变量和多变量 Cox 比例风险分析评估术前肺栓塞或其他临床变量是否与术后疾病复发或癌症特异性生存相关。
782 例肾细胞癌患者中,术前发现肺栓塞 35 例(4.4%)。术前有肺栓塞的患者更有可能有更高水平的血栓和更高的 T 分期(p<0.01)。两组在其他临床或病理特征方面无差异。术前诊断为肺栓塞的患者在 90 天死亡率无差异。在 395 例术前无转移的患者中,147 例(37.2%)在中位随访 22 个月时显示转移性肾细胞癌。肺栓塞患者的肾细胞癌复发率无差异(p=0.36)。术前有肺栓塞的患者肺部复发并不比无肺栓塞的患者更常见(p=0.71)。此外,术前肺栓塞并不能预测癌症特异性生存率更差(p=0.58)。
术前肺栓塞与肾细胞癌伴肿瘤血栓患者的早期死亡率、复发或癌症特异性生存率无相关性。